Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Italy Fines Apple €98.6 Million Over App Store Dominance 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
PARSIPPANY, N.J., Aug. 31, 2017 -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) will present at the 6th Annual Gateway investor conference, to be held on September 6-7, 2017 at the Four Seasons Hotel San Francisco. Interpace management is scheduled to present on Wednesday, September 6 at 9:00 a.m. Pacific time, with one-on-one meetings held throughout the conference.
The presentation will be webcast live and available for replay in the Investor Relations section of Interpace’s website at www.interpacedx.com or on the Gateway Conference website at www.gateway-conference.com/presenters. To receive additional information, request an invitation or to schedule a one-on-one meeting, please email [email protected].
About the Gateway Conference
The 6th Annual Gateway Conference is an invite-only conference presented by Liolios, which brings together the most compelling companies with the nation’s top institutional investors and analysts. This year’s event features more than 100 companies from a number of growth industries, including technology, business and financial services, consumer, digital media, clean technology and life sciences. The format has been designed to give attendees direct access to senior management via company presentations, Q&A sessions and one-on-one meetings. For more information, visit www.gateway-conference.com or www.liolios.com.
About Interpace Diagnostics Group, Inc.
Interpace Diagnostics is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The Company currently has three commercialized molecular tests; PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. Interpace Diagnostics' mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science.
CONTACTS: Interpace Diagnostics Group, Inc. Investor Relations: Paul Kuntz – RedChip [email protected]
